1 |
|
|
Conditions: |
|
Tuberculosis; HIV Infections |
Interventions: |
|
Biological: MVA85A (TB vaccine); Biological: MVA 85A |
|
2 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: SAAVI DNA-C2 vaccine; Biological: SAAVI MVA-C vaccine; Biological: Placebo |
|
3 |
|
|
Conditions: |
|
HIV Infections; Streptococcus Pneumoniae |
Interventions: |
|
Biological: pneumococcal conjugate vaccine; Biological: pneumococcal polysaccharide vaccine; Biological: pneumococcal polysaccharide vaccine |
|
4 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: Ad26.ENVA.01 HIV-1 vaccine |
|
5 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: Ad5.ENVA.48 HIV-1 vaccine |
|
6 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: Dendritic cell vaccine |
|
7 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: pGA2/JS7 DNA; Biological: Modified vaccinia Ankara/HIV62 |
|
8 |
|
|
Conditions: |
|
HIV Infections; Sexually Transmitted Diseases |
Intervention: |
|
Biological: Quadrivalent human papillomavirus vaccine |
|
9 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: HIV gp120/NefTat/AS02A Vaccine |
|
10 |
|
|
Conditions: |
|
HIV Infections; Hepatitis B |
Intervention: |
|
Behavioral: Enhanced HIV risk reduction and HIV vaccine education |
|
11 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: EP-1233; Biological: MVA-mBN32 |
|
12 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Other: Observation |
|
13 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: MVA-CMDR vaccine |
|
14 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: Autologous HIV-1 ApB DC Vaccine |
|
15 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Device: TriGrid™ Delivery System |
|
16 |
|
|
Conditions: |
|
HIV Seronegativity; HIV Infections |
Intervention: |
|
|
|
17 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: SCBaL/M9 |
|
18 |
|
|
Conditions: |
|
AIDS Vaccines; HIV Infections; HIV-1 |
Interventions: |
|
Drug: VRC-HIVADV027-00-VP; Drug: VRC-HIVADV038-00-VP |
|
19 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: HIV-1 gag DNA; Biological: IL-15 DNA adjuvant; Biological: IL-12 DNA adjuvant |
|
20 |
|
|
Conditions: |
|
HPV-16/18 Infections; Cervical Neoplasia |
Intervention: |
|
Biological: GSK Biologicals' HPV vaccine 580299 |
|
21 |
|
|
Conditions: |
|
Anal Cancer; HIV Infections |
Intervention: |
|
Biological: Gardasil |
|
22 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: Placebo |
|
23 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: DermaVir patch; Biological: Placebo patch |
|
24 |
|
|
Conditions: |
|
HIV Infections; Human Immunodeficiency Virus; Acquired Immune Deficiency Syndrome |
Interventions: |
|
Biological: HIV glycoprotein 140 ZM96 (vaccine); Biological: Carbopol 974 |
|
25 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: HIV-1 immunogen; Biological: HIV-1 Immunogen; Biological: HIV-1 Immunogen |
|
26 |
|
|
Condition: |
|
HIV Infection |
Intervention: |
|
|
|
27 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: PennVax B; Biological: IL-12; Biological: IL-15 |
|
28 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: Tat protein |
|
29 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: LC002 standard vaccination; Biological: LC002 high-dose vaccination; Biological: LC002 placebo vaccination |
|
30 |
|
|
Condition: |
|
HIV Infection |
Intervention: |
|
Biological: ADMVA |
|
31 |
|
|
Conditions: |
|
HIV Infections; TB |
Intervention: |
|
Biological: MVA 85A |
|
32 |
|
|
Conditions: |
|
HIV Infections; Hepatitis C |
Interventions: |
|
Biological: Twinrix; Biological: Decavac |
|
33 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: IMVAMUNE (MVA-BN); Biological: IMVAMUNE; Biological: IMVAMUNE |
|
34 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Drug: VRC-HIVADV014-00-VP |
|
35 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: MVA-mBN120B |
|
36 |
|
|
Condition: |
|
HIV-1 |
Interventions: |
|
Biological: ALVAC-HIV (vCP1521), sanofi pasteur; Biological: AIDSVAX B/E: Bivalent HIV gp120 |
|
37 |
|
|
Condition: |
|
HIV Infections |
Intervention: |
|
Biological: T cell vaccination |
|
38 |
|
|
Conditions: |
|
Influenza; HIV |
Intervention: |
|
Biological: Fluviral |
|
39 |
|
|
Condition: |
|
HIV |
Interventions: |
|
Biological: a DNA plasmid (pHIS-HIV-AE) encoding the HIV-1 AE antigens, modified Gag, Pol, Tat/Rev and Env; Biological: a non-replicating, recombinant fowlpox virus (rFPV-HIV-AE) encoding the HIV-1 AE antigens, modified Gag, Pol, Tat/Rev and Env |
|
40 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: pHIS-HIV-AE DNA Prime; Biological: rFPV-HIV-AE Booster; Biological: Placebo |
|
41 |
|
|
Conditions: |
|
Adherence; Community Outreach; HIV Risk Behaviors; Hepatitis A Vaccines; Hepatitis B Vaccines; Hepatitis C; Needle-Exchange Programs; Substance Abuse, Intravenous |
Intervention: |
|
Behavioral: Needle-Exchange Programs |
|
42 |
|
|
Condition: |
|
Precancerous/Nonmalignant Condition |
Interventions: |
|
Drug: E1M184V peptide vaccine; Drug: incomplete Freund's adjuvant; Drug: sargramostim; Procedure: immunoenzyme technique |
|
43 |
|
|
Conditions: |
|
Cervical Cancer; Precancerous/Nonmalignant Condition |
Interventions: |
|
Drug: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Procedure: DNA analysis; Procedure: colposcopic biopsy; Procedure: cytology specimen collection procedure; Procedure: polymerase chain reaction |
|
44 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: DermaVir Patch; Biological: DermaVir Placebo; Biological: DermaVir Patch; Biological: DermaVir Placebo; Biological: DermaVir Patch; Biological: DermaVir Placebo |
|
45 |
|
|
Condition: |
|
HIV Infections |
Interventions: |
|
Biological: MVA-B; Biological: Placebo |
|
46 |
|
|
Conditions: |
|
Cholera; Vibrio Infections; Diarrhea |
Interventions: |
|
Biological: CholeraGarde®; Biological: Placebo |
|
47 |
|
|
Condition: |
|
Pneumococcal Infections |
Interventions: |
|
Biological: Pneumovax or Pneumo23; Biological: Prevnar |
|